SEC Form 4 · accession 0001209191-19-008744

KYNTRA BIO, INC. · KYNB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Thomas B Neff

Officer — Chief Executive Officer · Director

Period of report

Feb 7, 2019

Accepted (ET)

Feb 8, 2019 · 6:58 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000921299

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Feb 7, 2019	M	10,319	$3.60	A	2,680,346	D
Common Stock^F2	Feb 7, 2019	S	19,015	$55.94	D	2,661,331	D
Common Stock^F3	Feb 7, 2019	S	5,013	$57.06	D	2,656,318	D
Common Stock^F4	Feb 7, 2019	S	3,847	$55.98	D	81,511	D
Common Stock^F5	Feb 7, 2019	S	487	$57.01	D	81,024	D
Common Stock	Feb 8, 2019	M	10,319	$3.60	A	2,666,637	D
Common Stock^F6	Feb 8, 2019	S	5,257	$56.54	D	2,661,380	D
Common Stock^F7	Feb 8, 2019	S	13,593	$57.05	D	2,647,787	D
Common Stock	Feb 8, 2019	S	50	$57.68	D	2,647,737	D
Common Stock^F8	Feb 8, 2019	S	818	$56.79	D	80,206	I	By Family Partnership
Common Stock	Feb 8, 2019	S	100	$57.68	D	80,106	I	By Family Partnership
Common Stock	holding	—	—		—	19,500	I	By Spouse
Common Stock^F9	holding	—	—		—	60,946	I	See footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F10	$3.60	Feb 7, 2019	M	10,319	D	—	Mar 11, 2019	Common Stock	10,319	30,957	D
Stock Option (Right to Buy)^F10	$3.60	Feb 8, 2019	M	10,319	D	—	Mar 11, 2019	Common Stock	10,319	20,638	D

Explanation of responses

F1Shares sold pursuant to a 10b5-1 plan.
F10Fully vested.
F2The shares were sold at prices ranging from $55.48 to $56.44. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3The shares were sold at prices ranging from $56.80 to $57.43. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4The shares were sold at prices ranging from $55.54 to $56.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5The shares were sold at prices ranging from $56.94 to $57.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6The shares were sold at prices ranging from $55.67 to $56.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7The shares were sold at prices ranging from $56.67 to $57.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F8The shares were sold at prices ranging from $56.58 to $57.08. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F9The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.